Pharmaceutical Development And Services
Pharmaceutical Development And Services is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/MOIRAI)
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with DLBCL-type Richter Transformation
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
Effect of nepafenac/dexamethasone fixed dose combination vs. its individual components (nepafenac and dexamethasone monotherapies) on postoperative inflammation after cataract surgery: a randomized, multicentre, blinded-assessor, parallel-group clinical study – NE.DE.F. STUDY
Sponsor Medivis S.r.l.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study With 2 Weeks of Follow-Up to Evaluate Safety and Efficacy of Two Different Dosages of Isocyclosporin A Eye Drop Solution Versus Vehicle in Adult Patients with Atopic Keratoconjunctivitis (AKC).
Sponsor Dompe' Farmaceutici S.p.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
RR001 in Combination with Chemotherapy for Patients with Locally Advanced Pancreatic Adenocarcinoma: Open-label, Non-randomized Dose Escalation Phase I/IIa Study
Sponsor Eir Biotherapies S.r.l.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL
Sponsor ASST Grande Ospedale Metropolitano Niguarda
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Pharmaceutical Development And Services?
The 2026-10-09 snapshot links Pharmaceutical Development And Services to 6 distinct CTIS trials. Recorded services include Clinical monitoring, Investigator recruitment, Project management, Regulatory services, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Pharmaceutical Development And Services?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Pharmaceutical Development And Services conducted?
The linked trials record locations in 14 countries, including Italy, Austria, Germany, Denmark, Ireland. These are trial locations, not confirmed office locations or countries where Pharmaceutical Development And Services delivered services.
What can this page tell me about Pharmaceutical Development And Services's trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Pharmaceutical Development And Services. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Pharmaceutical Development And Services S.r.l.